Short answer
Beam Therapeutics Inc. (BEAM) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
Beam Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Exhibit 99.1 contains the substantive earnings release and financial details
- Results announcement provides investors an update on Beam’s quarterly operating performance
Item EX-99.1 · Exhibit EX-99.1
- Q3 net loss widened to $134.4M, or $1.28 per share, from $112.6M, or $1.10, despite R&D remaining near $110.1M
- Cash, equivalents and marketable securities fell to $1.0B from $1.2B at December 31, 2025
- Additional $200M Sixth Street borrowing expected to extend funding into mid-2029, subject to borrowing conditions
- Risto-cel BLA submission targeted as early as year-end 2026, creating a potential near-term regulatory catalyst in sickle cell disease
- BEAM-302 pivotal-cohort dosing expected complete in the first half of 2027, while BEAM-304 dosing is planned for early 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Beam Therapeutics Inc. 8-K filings
Get the next BEAM 8-K as it lands
Follow BEAM for push alerts, or ask the research agent what this filing means.